News | April 04, 2022
USFDA grants priority review to Roche’s Actemra/RoActemra to treat Covid-19
If approved, it will be the first USFDA-approved immunomodulator for the treatment of Covid-19 in hospitalised patients
If approved, it will be the first USFDA-approved immunomodulator for the treatment of Covid-19 in hospitalised patients
Additional data across neurological disorders, including Alzheimer’s disease, help advance the scientific understanding of these conditions and the potential impact of early treatment
Recommendation is based on pivotal data from the phase III POLARIX study
Vabysmo is the only injectable eye medicine approved simultaneously in the US for wet AMD and DME, with flexible dosing regimens based on patient need
Evrysdi is approved in 70 countries and submitted in a further 31 with more than 4,500 patients treated to date
Gavreto is the first and only precision medicine approved in the EU for first-line treatment of people with RET fusion-positive advanced NSCLC
Data demonstrates Ronapreve reduced risk of hospitalisation in certain patients and reduced risk of symptomatic Covid-19 infections in people exposed to the virus
A final decision regarding the approval of Ronapreve is expected from the European Commission shortly
The implant is surgically inserted into the eye during a one-time, outpatient procedure and refilled every six months
Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting
Subscribe To Our Newsletter & Stay Updated
